KUMAMOTO AIDS Seminar


16th KUMAMOTO AIDS Seminar

Pictures
■ October 7th,Wednesday 　9:00-17:30	■ Poster Session
■ October 8th, Thursday 　13:00-17:45	October 8th, Thursday 　13:00-14:30
■ October 9th, Friday　 9:00-14:45	October 9th, Friday 　11:50-13:30

■ October 7th, Wednesday	Hotel Nikko Kumamoto 9:00-17:30

	Hiroaki Mitsuya [NCGM / Kumamoto University]		Opening Remarks
Session I			9:10-10:25 〔75〕
Session I			Chairs: Hiroaki Mitsuya & Shuzo Matsushita
	O-1-01	Robert Murphy Northwestern University, USA	Progress in HIV Therapy
	O-1-02	Hiroaki Mitsuya NCGM / Kumamoto University, Japan	Structure-guided development of molecular-targeting antiviral agents for treatment of HIV infection and AIDS
10:25-10:40 〔15〕	Coffee Break
Session II			10:40-12:10 〔90〕
Session II			Chairs: Shinich Oka & Wataru Sugiura
	O-1-03	Wataru Sugiura NMC / GSK, Japan	Molecular epidemiology of acquired and transmitted drug resistant HIV in Japan
	O-1-04	Takeshi Nishijima NCGM, Japan	Management of chronic kidney diseases in HIV-1-infected patients in the era of “treatment for all” strategy
	O-1-05	Yorifumi Satou Kumamoto University, Japan	Clonality of HIV-1-infected cells in PBMCs of HIV-1-infected individuals
12:10-13:30 〔80〕	Lunch
Session III			13:30-14:30 〔60〕
Session III			Chairs: Seiji Okada & Shinya Suzu
	O-1-06	Takeo Kuwata Kumamoto University, Japan	Impact of gp41 mutations for escape from a broad neutralizing antibody against SIV
	O-1-07	Takamasa Ueno Kumamoto University, Japan	Relative resistance of HLA-B to down-regulation by naturally-occurring HIV-1 Nef sequences
Session IV			14:30-15:45 〔75〕
Session IV			Chairs: Tetsuro Matano & Takamasa Ueno
	O-1-08	Takuya Yamamoto NIBIO / Kumamoto University, Japan	CD150 signal modulation enhances SHIV-specific TFH cell responses
	O-1-09	Rebecca Lynch NIAID, NIH, USA	Impact of broadly neutralizing antibody VRC01 on HIV-1 after infusion into chronically infected subjects
15:45-16:00 〔15〕	Coffee Break
Session V			16:00-16:45 〔45〕
Session V			Chair: Masafumi Takiguchi
	O-1-10	Victor Appay INSERM, France	CD8+ T cell efficacy and preservation of immune resources in HIV infection
Session VI			16:45-17:30 〔45〕
Session VI			Chair: Shuzo Matsushita
	O-1-11	Dan H. Barouch Harvard Medical, USA	Novel HIV Vaccine and Eradication Strategies

>> Oct. 8 　

Home (Japanese)

Home (English)

Center for AIDS Research HP